https://doi.org/10.4081/ejtm.2023.11894
Potential of molecular biophysical stimulation therapy in chronic musculoskeletal disorders: a narrative review
Submitted: 30 September 2023
Accepted: 29 October 2023
Published: 9 November 2023
Accepted: 29 October 2023
Abstract Views: 1144
PDF: 376
HTML: 6
HTML: 6
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Current treatment of chronic musculoskeletal diseases does not give sufficient results despite the implementation of novel drugs and techniques in orthopaedics and physical therapy. For instance, osteoporosis treatment is currently mainly limited to drug application, while the goal of osteoarthritis treatment is to mitigate pain symptoms through physical therapy. The main therapeutic principle in the management of osteoporosis is not only to increase bone mass, but also to improve bone and the cartilage quality, which depends on the biomechanical balance. Therefore, there is a strong demand for advanced technologies that would safely and non-invasively accelerate cartilage regeneration and improve bone density. Ten years ago, a new state-of-the-art technology - “Molecular biophysical stimulation therapy (MBST)”, specifically nuclear magnetic resonance therapy, emerged on the medical technology market and until now, it has shown successful results in the conservative treatment of musculoskeletal disorders, including back pain. The aim of this review is to provide an integrated, synthesized overview of the current evidence of efficacy of MBST for managing chronic musculoskeletal disorders.
Hore PJ. Nuclear magnetic resonance. New York: Oxford University Press; 2015.
DOI: https://doi.org/10.1093/hesc/9780198703419.001.0001
Burghoff M, Hartwig S, Trahms L, Bernarding J. Nuclear magnetic resonance in the nanoTesla range. Appl Phys Lett. 2005;87(5):054103.
DOI: https://doi.org/10.1063/1.2006981
Krpan D. MBST-Nuclear Magnetic Resonance Terapy - the new possibility of osteoarthritis and osteoporosis treatment. Dijagnostica I Lecenje Osteoporoze. 2018;35, 61-66.
Digel I, Kurulgan E, Linder P, Kayser P, Porst D, Braem GJ, Zerlin K, Artmann GM, Artmann AT. Decrease in extracellular collagen crosslinking after NMR magnetic field application in skin fibroblasts. Med Biol Eng Comput. 2007 Jan;45(1):91-7. Epub 2007 Jan 3. PMID: 17203317.
DOI: https://doi.org/10.1007/s11517-006-0144-z
Levers A, Staat M, Laack Wv. Analyse der Langzeitwirkung der MBST® KernspinResonanzTherapie bei Gonarthrose. Orthopädische Prax. 2011; 47:11.
Steinecker-Frohnwieser B, Lohberger B, Eck N, Mann A, Kratschmann C, Leithner A, Kullich W, Weigl L. Nuclear Magnetic Resonance Therapy Modulates the miRNA Profile in Human Primary OA Chondrocytes and Antagonizes Inflammation in Tc28/2a Cells. Int J Mol Sci. 2021 May 31;22(11):5959. PMID: 34073090; PMCID: PMC8198628.
DOI: https://doi.org/10.3390/ijms22115959
Temiz-Artmann A, Linder P, Kayser P, Digel I, Artmann GM, Lücker P. NMR in vitro effects on proliferation, apoptosis, and viability of human chondrocytes and osteoblasts. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):391-4. PMID: 16179956.
DOI: https://doi.org/10.1358/mf.2005.27.6.896831
Krpan D. MBST-Nuclear Magnetic Resonance Therapy in the Treatment of Osteoarthritis, the Long-Term Follow Up-Case Report. Biomed J. 2018;1(3):8383-8375.
Krpan D, Kullich W. Nuclear magnetic resonance therapy (MBST) in the treatment of osteoporosis. Case report study. Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):235-238. Epub 2017 Oct 25. PMID: 29263740; PMCID: PMC5726216.
DOI: https://doi.org/10.11138/ccmbm/2017.14.1.235
Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 Jun 9;391(10137):2368-2383. Epub 2018 Mar 21. PMID: 29573872.
DOI: https://doi.org/10.1016/S0140-6736(18)30489-6
Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017 Nov;5(11):898-907. Epub 2017 Jul 7. PMID: 28689769; PMCID: PMC5798872.
DOI: https://doi.org/10.1016/S2213-8587(17)30188-2
Thysen S, Luyten FP, Lories RJ. Targets, models and challenges in osteoarthritis research. Dis Model Mech. 2015 Jan;8(1):17-30. PMID: 25561745; PMCID: PMC4283647.
DOI: https://doi.org/10.1242/dmm.016881
Oliva R, Jansen B, Benscheidt F, Sandbichler AM, Egg M. Nuclear magnetic resonance affects the circadian clock and hypoxia-inducible factor isoforms in zebrafish. Biol Rhythm Res. 2019;50(5):739-57.
DOI: https://doi.org/10.1080/09291016.2018.1498194
Mann A, Steinecker-Frohnwieser B, Naghilou A, Millesi F, Supper P, Semmler L, Wolf S, Marinova L, Weigl L, Weiss T, Radtke C. Nuclear Magnetic Resonance Treatment Accelerates the Regeneration of Dorsal Root Ganglion Neurons in vitro. Front Cell Neurosci. 2022 Mar 28;16:859545. PMID: 35418835; PMCID: PMC8995532.
DOI: https://doi.org/10.3389/fncel.2022.859545
Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010 Aug;26(3):355-69. Erratum in: Clin Geriatr Med. 2013 May;29(2):ix. PMID: 20699159; PMCID: PMC2920533.
DOI: https://doi.org/10.1016/j.cger.2010.03.001
Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S120-4. PMID: 19026154.
Lories RJ. Fast Facts: Osteoarthritis. Oxford: Oxford University Press; 2009.
Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 2012 Jan 1;85(1):49-56. Erratum in: Am Fam Physician. 2012 Nov 15;86(10):893. PMID: 22230308.
Yusuf E. Pharmacologic and non-pharmacologic treatment of osteoarthritis. Curr Treat Options Rheumatol. 2016;2(2):111-25.
DOI: https://doi.org/10.1007/s40674-016-0042-y
Froböse I, Eckey U, Reiser M, Glaser C, Englmeier F, Assheur J. Evaluation of the effectiveness of three-dimensional pulsating electromagnetic fields of the MultiBioSignal Therapy (MBST) in respect to the regeneration of cartilage structures. Orthopadische Prax. 2000;36(510):e5.
Kullich W, Fagerer N. Anwendung der Kernspinresonanz als neue Therapiemöglichkeit bei Gonarthrose. Arzt & Praxis. 2007;61(927):180-2.
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011 Apr 9;377(9773):1276-87. Epub 2011 Mar 28. PMID: 21450337; PMCID: PMC3555696.
DOI: https://doi.org/10.1016/S0140-6736(10)62349-5
Poole KE, Compston JE. Osteoporosis and its management. BMJ. 2006 Dec 16;333(7581):1251-6. PMID: 17170416; PMCID: PMC1702459.
DOI: https://doi.org/10.1136/bmj.39050.597350.47
Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D. Osteoporosis: A Review of Treatment Options. P T. 2018 Feb;43(2):92-104. PMID: 29386866; PMCID: PMC5768298.
Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010 Nov 18;363(21):2027-35. PMID: 21083387.
DOI: https://doi.org/10.1056/NEJMct1004903
Kamel HK. Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc. 2007 Sep;8(7):434-40. PMID: 17845945.
DOI: https://doi.org/10.1016/j.jamda.2007.06.005
Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M, Laskou F, Dennison EM, Cooper C, Patel HP. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021 Apr;33(4):759-773. Epub 2021 Mar 20. PMID: 33742387; PMCID: PMC8084810.
DOI: https://doi.org/10.1007/s40520-021-01817-y
Krpan D, Stritzinger B, Lukenda IL, Overbeck J, Kullich W. Non-pharmacological treatment of osteoporosis with Nuclear Magnetic Resonance Therapy (NMR-Therapy). Period Biol. 2015;117(1):161-5.
Melzer C. Scientific evaluation of the MBST Magnetic Resonance Technology regarding the therapeutic potential and proof of clinical efficacy. Available from: https://www.thebodyworksclinic. com/wp-content/uploads/2019/02/20182_CER_ Scientific_Evaluation_of_MBST-Therapy_Melzer-Kullich_GB-1.pdf
Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ. 2006 Jun 17;332(7555):1430-4. PMID: 16777886; PMCID: PMC1479671.
DOI: https://doi.org/10.1136/bmj.332.7555.1430
Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009 Jan-Feb;22(1):62-8. PMID: 19124635; PMCID: PMC2729142.
DOI: https://doi.org/10.3122/jabfm.2009.01.080102
Illés ST. A derékfájás: mikor és mit tegyünk? [Low back pain: when and what to do]. Orv Hetil. 2015 Aug 16;156(33):1315-20. Hungarian. PMID: 26256495.
DOI: https://doi.org/10.1556/650.2015.30232
Kullich W, Schwann H, Walcher J, Machreich K. The effect of MBST®-NuclearResonanceTherapy with a complex 3-dimensional electromagnetic nuclear resonance field on patients with Low Back Pain. J Back Musculoskelet Rehabil. 2006;19(2-3):79-87.
DOI: https://doi.org/10.3233/BMR-2006-192-307
Salomonowitz G, Salfinger H, Hahne J, Friedrich M. Effekte der Kernspinresonanztherapie auf Krankenstand bei Patienten mit Nervenwurzelirritation infolge eines lumbalen Bandscheibenvorfalls [Impact of magnetic resonance therapy on sickness absence of patients with nerve root irritation following a lumbar disc problem]. Z Orthop Unfall. 2011 Oct;149(5):575-81. German. Epub 2011 Oct 7. PMID: 21984428.
DOI: https://doi.org/10.1055/s-0031-1280121
How to Cite
Žnidarič, M., Kozinc, Z., & Škrinjar, D. (2023). Potential of molecular biophysical stimulation therapy in chronic musculoskeletal disorders: a narrative review. European Journal of Translational Myology, 33(4). https://doi.org/10.4081/ejtm.2023.11894
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.